Evoke Pharma and EVERSANA Expand Patient Access to GIMOTI® With New Telehealth Solution
August 16, 2022 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif. and CHICAGO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company primarily focused on treatments for gastrointestinal (GI)...
Evoke Pharma Reports Second Quarter 2022 Financial Results
August 10, 2022 16:05 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases,...
Evoke Pharma to Report Second Quarter Results on August 10, 2022
August 03, 2022 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today...
Evoke Pharma Recognizes Gastroparesis Awareness Month through its Support of The International Foundation for Gastrointestinal Disorders (IFFGD)
August 01, 2022 08:30 ET
|
Evoke Pharma, Inc.
Ranked #1 in IFFGD Virtual Walk to spread awareness and support research for gastrointestinal disorders Evoke attending ANMS 2022 meeting August 5-7 in Philadelphia, PA SOLANA BEACH, Calif.,...
Evoke Pharma Expands IP Portfolio with Addition of Canadian Patent Covering GIMOTI Method of Use
July 06, 2022 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma Announces Approval of GIMOTI® to Florida State Medicaid Program
June 15, 2022 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., June 15, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma Regains Compliance with Nasdaq Listing Requirements and Provides Financial Update
June 08, 2022 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Real-World Data Analysis Reveals a Lower Risk of Tardive Dyskinesia (TD) with Metoclopramide than Previously Reported
May 23, 2022 07:00 ET
|
Evoke Pharma, Inc.
Presented as a Poster of Distinction at Digestive Disease Week (DDW) 2022, showed a 98.8 per 100,000 (0.1%) incidence of TD among gastroparesis patients treated with metoclopramide Supports Safety...
Patient Experience Survey Reported Positive Findings for GIMOTI®
May 18, 2022 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif. and CHICAGO, May 18, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, and...
Evoke Pharma to Present at H.C. Wainwright Global Investment Conference
May 17, 2022 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...